Intravenous immunoglobulin - Indications and mechanisms in cardiovascular diseases

被引:62
|
作者
Udi, Nussinovitch [1 ,2 ]
Yehuda, Shoenfeld [1 ,2 ,3 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, WM Keck Autoimmune Dis Ctr, IL-52621 Tel Hashomer, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Laura Schwarz Kipp Chair Res Autoimmune Dis, IL-69978 Tel Aviv, Israel
关键词
intravenous immunoglobulins (IVIG); heart failure; dilated cardiomyopathy; autoimmunity; tumor necrosis factor alpha (TNF alpha);
D O I
10.1016/j.autrev.2008.04.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intravenous immutioglobulin (IVIG) is efficient in various immune mediated conditions. Various cardiovascular diseases are mediated by inflammatory processes and autoimmune mechanisms. Therefore, it seems conceivable to employ IVIG as an immunomodulating therapy in such indications. In this paper we review the possible anti-inflammatory effects of WIG transfusion, and discuss the possible clinical implications in cardiology. Besides the established use of IVIG in Kawasaki disease, IVIG may be beneficial in some cases of heart failure, dilated cardiomyopathy, myocarditis, pericardial diseases, neonatal lupus, in the prevention of cardiac rejection following transplantation, and in modulating atherosclerosis. IVIG has been proven to be ineffective in rheumatic fever. Although uncommon, complications may arise including myocardial infarction, renal failure and hyperviscosity. IVIG should be administered based on accepted modes of transfusion. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 50 条
  • [1] Intravenous immunoglobulin - Indications and mechanisms in cardiovascular diseases (vol 7, pg 445, 2008)
    Udi, Nussinovitch
    Shoenfeld, Yehuda
    [J]. AUTOIMMUNITY REVIEWS, 2010, 9 (04) : 246 - 246
  • [2] Intravenous immunoglobulin-indications and mechanisms in cardiovascular diseases (vol 7, pg 445, 2008)
    Nussinovitch, Udi
    Shoenfeld, Yehuda
    [J]. AUTOIMMUNITY REVIEWS, 2011, 10 (03) : 180 - 180
  • [3] Intravenous immunoglobulin - New indications and mechanisms of action
    Shoenfeld, Y
    Gershwin, ME
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 29 (03) : 165 - 166
  • [4] Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases
    Bayry, J
    Thirion, M
    Misra, N
    Thorenoor, N
    Delignat, S
    Lacroix-Desmazes, S
    Bellon, B
    Kaveri, S
    Kazatchkine, MD
    [J]. NEUROLOGICAL SCIENCES, 2003, 24 (Suppl 4) : S217 - S221
  • [5] Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases
    Kazatchkine, MD
    Bayry, J
    Lacroix-Desmazes, S
    Kaveri, SV
    [J]. INTRAVENOUS IMMUNOGLOBULINS IN THE THIRD MILLENNIUM, 2004, : 105 - 111
  • [6] Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases
    J. Bayry
    M. Thirion
    N. Misra
    N. Thorenoor
    S. Delignat
    S. Lacroix-Desmazes
    B. Bellon
    S. Kaveri
    M. D. Kazatchkine
    [J]. Neurological Sciences, 2003, 24 : s217 - s221
  • [7] Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular diseases
    Sharshar, T
    Kaveri, S
    Kazatchkine, M
    [J]. CLINICAL NEUROPHYSIOLOGY: FROM RECEPTORS TO PERCEPTION, 1999, 50 : 486 - 492
  • [8] Mechanisms of action of intravenous immunoglobulin in immune-mediated diseases
    Kazatchkine, MD
    [J]. INTRAVENOUS IMMUNOGLOBULIN: RESEARCH AND THERAPY, 1996, : 29 - 41
  • [9] History, biological mechanisms of action and clinical indications of intravenous immunoglobulin (IVIG) preparations
    Teeling, JL
    Bleeker, WK
    Hack, CE
    [J]. REVIEWS IN MEDICAL MICROBIOLOGY, 2002, 13 (03) : 91 - 100